BLITZ-AF Cancer

 Private Area

Presentazione Progetto

BLITZ-AF Cancer is a multicenter, non-interventional study on patients with atrial fibrillation (AF) and cancer (diagnosed within the last 3 years prior to enrolment) promoted by the Heart Care Foundation - Fondazione per il Tuo Cuore ONLUS.
AF and cancer frequently coexist. Since these patients are usually excluded from randomized trials, information on their management and outcome is scarce. Specifically, the occurrence of relevant clinical events, such as ischemic and hemorrhagic stroke, systemic embolic events (SEE), venous thromboembolic events (VTE), major bleedings (ISTH criteria), all-cause mortality, cardiovascular (CV) mortality occurring in patients treated or not with antithrombotic agents needs to be clarified.
The primary objective of the BLITZ-AF Cancer registry is to collect updated information on the clinical epidemiology and the management of patients with AF and a documented diagnosis of cancer (occurring prior or after the diagnosis of AF) in a real-world setting, with a specific focus on the use of antithrombotic treatments.
The study will continue till the consecutive recruitment of 1500 patients (it is assumed that approximately 1000 patients will be treated with antithrombotic agents). The recruitment period will last approximately 24 months. Each patients will be followed up for 1 year.
Participating centers will be approximately 80 in Italy and 50 distributed in other European countries (Belgium, Germany, Ireland, Portugal, Spain, The Netherlands, Turkey) with 3-20 sites per Country.
Data will be collected using a web based system.